Why basal thumb OA is harder to treat than it looks

For many patients, basal thumb arthritis arrives as a slow narrowing of ordinary life — pain when turning a key, opening a jar, gripping a pen — long before anyone would consider an operation. That in-between territory is precisely where conventional treatment runs out of answers.

The trapeziometacarpal (TMC) joint sits where the thumb meets the wrist, and despite its small size it bears substantial load during gripping and pinching. As the cartilage surface degrades across the Eaton-Littler spectrum from early-stage irregularity (grades I–II) through to established joint-space loss (grades III–IV), the joint becomes progressively less able to absorb that mechanical stress. Prevalence reaches roughly 30% in postmenopausal women, making this the second most common degenerative hand condition after distal interphalangeal OA.

Corticosteroid injections can quieten an inflamed flare for a few months; hyaluronic acid offers lubrication. Neither addresses the underlying cartilage deficit, and relief tends to diminish with each successive injection. At the other end of the pathway, trapeziectomy — removal of the trapezium bone — remains the UK surgical gold standard and is genuinely effective, but it is irreversible, carries a meaningful recovery period, and is appropriately reserved for more advanced disease.

That leaves a substantial group of patients whose OA is confirmed, whose symptoms limit daily function, and for whom surgery is not yet indicated or not yet wanted. It is this intermediate group — not yet surgical candidates, but beyond what temporary injections can adequately manage — where the therapeutic gap is most acutely felt.

How ChondroFiller works as an injectable collagen scaffold

ChondroFiller (Meidrix Biomedicals GmbH) is a CE-marked Class III medical device — a regulatory classification that reflects independent conformity assessment, not self-certification. The product itself is an acellular, murine-derived Type I collagen hydrogel supplied as a liquid. Once placed inside the joint under ultrasound guidance, it gels within approximately three to five minutes, forming a stable three-dimensional scaffold that conforms to the space available.

The biological mechanism is called acellular matrix-induced chondrogenesis. The collagen structure acts as a chemotactic signal, drawing the patient's own progenitor cells — resident in the surrounding synovium and subchondral bone — into the scaffold, where they can differentiate and deposit cartilage-like matrix as the collagen gradually degrades. No cells are harvested beforehand, no donor tissue is used, and no laboratory culture step is required. This single-step, acellular approach is what distinguishes ChondroFiller from autologous cell-based therapies, which typically demand a prior harvesting procedure weeks or months earlier.

It is equally important to distinguish the product from permanent hydrogel fillers such as polyacrylamide gel (PAAG): those compounds remain in the joint indefinitely and work through mechanical cushioning rather than biological repair. ChondroFiller is a temporary scaffold that promotes the body's own repair processes — not a filler and not a claim to regrow cartilage outright.

The product has been in European clinical use for over a decade, with more than 19,000 cases performed across the knee, hip, ankle, and small joints.

What happens during a ChondroFiller thumb injection

The appointment is built around a single outpatient visit. No general anaesthetic is required, there is no theatre admission, and patients leave the clinic the same day.

After reviewing any existing imaging, the clinician applies local anaesthetic to the base of the thumb. Under continuous ultrasound guidance — the same real-time imaging used routinely in musculoskeletal practice to visualise joints and soft tissues — a needle is positioned precisely within the trapeziometacarpal joint space. The collagen hydrogel is then delivered directly to the site of cartilage damage, where it begins to establish at the treatment site before the needle is withdrawn.

No incisions are made, and the appointment does not involve a surgical wound or theatre recovery. The entire process takes place in the clinic, with the patient seated throughout and able to leave under their own steam afterwards.

In the days following the injection, most patients are advised to limit forceful pinching and gripping while the scaffold settles into position. The precise activity guidance — how long to modify use and which movements to protect — depends on the individual joint and the extent of damage treated, and the treating clinician will go through this at the appointment itself.

What the clinical evidence shows

The direct evidence comes from two peer-reviewed prospective cohort studies by Corain and colleagues. In the larger — published in 2025 and indexed as PMC12213533 — 64 patients with trapeziometacarpal OA across the full Eaton-Littler spectrum (grades I–IV) received a single ultrasound-guided ChondroFiller injection. All primary outcome measures — NRS pain scores, DASH functional disability questionnaire scores, and both Jamar grip and pinch strength — improved significantly (P<0.001) and remained improved at the longest follow-up point, which exceeded two years. No adverse events were recorded across the entire cohort.

An earlier 2023 study by the same group (n=43) replicated the pattern at six months, assessing early-stage (grades I–II) and advanced-stage (grades III–IV) patients separately.

The most substantial gains in both studies fell within the two-to-six months post-injection window. The scaffold takes time to recruit the body's own progenitor cells, and the repair process that follows is gradual rather than immediate — a realistic expectation to hold from the outset.

A stage-stratified finding is worth noting for patients at different points of the disease. Those with earlier-stage OA (grades I–II) gained more in grip and pinch strength, while those at more advanced stages (grades III–IV) showed greater improvement on the DASH functional disability score. Both groups benefited — but through different functional mechanisms.

Supporting evidence for ChondroFiller in small joints comes from a separate 2025 wrist study (Demmer et al., PMC12498443), where treated patients showed significantly better cartilage quality at follow-up than controls (Outerbridge median 1.5 vs 3, P=0.006; ICRS score 1 vs 3, P=0.002). This is wrist evidence, not thumb evidence, but it reinforces the product's applicability in anatomically constrained spaces.

The current evidence base is observational rather than randomised controlled trial data, and published follow-up beyond two years does not yet exist. These are genuine limitations — but they do not change what the existing studies consistently found across two independent cohorts and more than 100 patients.

Which patients are most likely to benefit

Not every patient with the same Eaton-Littler grade on imaging is the same clinical candidate — and that distinction is where the candidacy assessment actually begins.

The grading system tells a clinician how far structural deterioration has progressed radiographically, but it does not capture symptom burden, daily functional loss, or — critically — whether the joint retains enough residual architecture to support scaffold integration. In the Corain studies, patients across all four grades showed meaningful improvements, though the functional pathways differed: earlier-stage patients (grades I–II) tended to gain more in grip and pinch strength, while those at grades III–IV showed greater improvement in daily functional scores. Both trajectories are clinically relevant; neither makes the grade alone a simple green or red light.

Patients who present most naturally for this conversation have typically already tried corticosteroid or hyaluronic acid injections and found the relief either too short-lived or insufficient relative to their functional limitation. That treatment history matters: it indicates structural involvement that palliative measures cannot adequately address.

Two clinical factors specifically require flagging at assessment. First, ChondroFiller is a murine-derived collagen product — patients with known hypersensitivity to animal-derived proteins need to raise this before the appointment. Second, very advanced joint-space collapse, where little viable architecture remains, typically shifts the conversation toward surgical options rather than scaffold injection.

A structured assessment covering current imaging, functional evaluation, and prior treatment response is what determines suitability in a given case. The Eaton-Littler grade is the starting framework; arriving at an appropriate recommendation requires the full clinical picture.

Arranging an assessment: cost, access, and what comes next

Practical access in the UK is currently limited to a small number of specialist centres. In London, assessment and treatment are available at London Cartilage Clinic, 66 Harley Street, where Professor Paul Lee leads the programme — the clinic was the first in the UK to offer ChondroFiller as an outpatient ultrasound-guided service for the thumb and other joints. The treatment is self-funded; it is not available on the NHS, is not typically covered by standard private medical insurance, and is not available in the United States.

The guide cost for a thumb ChondroFiller injection is £3,000–£8,000 all-inclusive, with the specific figure confirmed at consultation based on individual clinical factors. That range reflects genuine variation in treatment requirements rather than a fixed price list.

The first step is a consultation covering current imaging, symptom history, prior treatment response, and direct examination of the joint. That conversation determines whether ChondroFiller is appropriate at this stage, or whether a different pathway — further conservative care, an alternative injection, or surgical referral — is more suitable, and what the realistic timeline and expectations should look like.

For patients who have reached the limit of what palliative injections can offer and are not yet at the point where irreversible surgery is the right answer, that assessment is a reasonable and proportionate next step. To arrange one, visit londoncartilage.com.